Clinical

Panelists discuss how monitoring patients with iron deficiency anemia requires regular follow-up appointments to track laboratory values, assess symptom improvement (particularly fatigue), and evaluate treatment response while considering the impact of comorbid conditions, with adjustments to therapy made based on both objective markers and patient-reported outcomes.

Real-world analyses have confirmed the efficacy of the 2-drug regimen of dolutegravir and lamivudine in treating HIV, confirming phase 3 testing results.

Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical interventions, increased adoption of minimally invasive techniques, and a greater focus on fertility preservation and sentinel lymph node procedures.

Waist circumference and waist-to-hip ratio show stronger links to colorectal cancer (CRC) than body mass index (BMI), a new study has found.

The panelist discusses how recurrent Clostridioides difficile infections represent a critical health care challenge, characterized by unmet needs in long-term prevention, microbiome restoration, and personalized treatment. The field is evolving toward precision medicine approaches, leveraging advanced diagnostics, innovative therapeutic modalities such as engineered probiotics and bacteriophage therapies, and comprehensive strategies that integrate microbial, immunological, and genetic insights to improve patient outcomes.

The panelist discusses how recurrent Clostridioides difficile infections are frequently associated with complex comorbidities including inflammatory conditions, immunocompromise, gastrointestinal disorders, and metabolic diseases. Management requires a nuanced, multidisciplinary approach focusing on tailored antibiotic strategies, immunomodulation, comprehensive diagnostics, and personalized treatment plans.

Artificial intelligence (AI) models, particularly artificial neural networks and machine learning, outperform traditional methods in predicting post–complete cytoreduction outcomes in patients with ovarian cancer, including overall survival, no residual disease, and postoperative complications.

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.

Generalized myasthenia gravis (gMG) is an autoantibody-driven chronic disease for which there is no cure.

Panelist discusses how delayed medical diagnosis causes significant economic burden through increased treatment costs, prolonged health care interventions, reduced patient productivity, and higher health care system expenses. Economic mitigation strategies include implementing early screening programs, improving diagnostic technologies, enhancing medical training, and developing robust health care infrastructure that prioritizes timely patient assessment and intervention.

Charleston Area Medical Center (AMC) Vandalia Health was among 3 participants in the Association of Cancer Care Centers' Quality Improvement Program for myeloproliferative neoplasms.

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment options in the relapsed/refractory setting.

Patients with diabetes and chronic kidney disease receiving physiologic insulin resensitization had much lower annual costs of care than similar patients not receiving it.

Besides Kent Hospital, the Association of Cancer Care Centers worked with Perlmutter Cancer Center at NYU Langone Hospital and Charleston Area Medical Center Vandalia Health in Charleston, West Virginia.

Panelists discuss how diagnosing iron deficiency anemia requires comprehensive laboratory testing of iron parameters alongside clinical assessment, emphasizing early detection to prevent complications in patients with common comorbidities like chronic kidney disease, heart failure, and inflammatory bowel disease, where coordinated treatment approaches must balance managing both IDA and the underlying condition.

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.

Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality improvement initiative in myeloproliferative neoplasms (MPNs).

Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on data from 2 phase 3 trials: BE OPTIMAL and BE COMPLETE.

Although the association between HIV and long COVID was inconclusive, the prevalence of long COVID in patients with HIV was high.

Patients with stage III epithelial ovarian cancer (EOC) and no visible residual disease after primary cytoreductive surgery had significantly longer real-world progression-free survival and time to next treatment when treated with first-line maintenance niraparib compared with those with higher-risk disease.

Men who have sex with men (MSM) can now participate in National Blood Donor Month under the FDA's updated guidelines, marking a crucial step toward addressing blood shortages and promoting inclusivity.

Across 5 research centers, investigators evaluated the impact of eculizumab on thymoma-associated myasthenia gravis, a severe disease subtype.

Some populations face significant disparities in accessing lung cancer screening facilities, with American Indian/Alaska Native (AI/AN)-majority and rural census tracts facing the greatest travel distances.

A panelist discusses how strategic managed care partnerships can streamline care transitions between treatment settings to ensure uninterrupted support and monitoring for patients with Lambert-Eaton myasthenic syndrome.